• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 432627 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1413952353 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1413952353 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Stock Investors Sell Off Shares of Ariad Pharmaceuticals, Down 1.4%

Published on Wed, 01/30/2013 - 13:25
By Adrienne Chilton

One of today's stocks on the move is Ariad Pharmaceuticals (NASDAQ:ARIA), down 1.4% to $20.05. The S&P is currently trading fractionally lower to 1,507 and the Dow Jones Industrial Average is trading fractionally higher to 13,956.

Ariad Pharmaceuticals has overhead space with shares priced $20.05, or 30.1% below the average consensus analyst price target of $28.69. Ariad Pharmaceuticals shares should encounter resistance at the 50-day moving average (MA) of $20.76 and support at its 200-day MA of $19.67.

In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $13.92 and a high of $25.40 and are now at $20.05, 44% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has declined 0.2%.

ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Rentrak Looks to Continue to Trade Above...

Rentrak (NASDAQ:RENT) traded at a new 52-week high today of $76.50. So far today appro ...

Watch for Continued Gains in Shares of O...

Shares of O'Reilly Automotive (NASDAQ:ORLY) traded today at $158.93, breaking its 52-we ...

Netease.com: The Winning Streak Continue...

Netease.com (NASDAQ:NTES) traded at a new 52-week high today of $94.97. This new high ...

Watch for Continued Gains in Shares of N...

Shares of Nautilus (NYSE:NLS) traded at a new 52-week high today of $13.41. This new h ...

Watch for Continued Gains in Shares of M...

Micron Technology (NASDAQ:MU) traded at a new 52-week high today of $30.93. This new h ...

Monster Worldwide Looks to Continue to T...

Monster Worldwide (NASDAQ:MNST) traded today at a new 52-week high of $99.05. So far t ...

Watch for Continued Gains in Shares of L...

Landstar System (NASDAQ:LSTR) traded at a new 52-week high today of $74.02. So far tod ...

Shares of Kilroy Realty Rise to a New 52...

Shares of Kilroy Realty (NYSE:KRC) traded at a new 52-week high today of $64.36. This ...